Armata Pharmaceuticals, Inc. (ARMP)

Insider Trading Filed: 2026-04-28

Director Daniel Gilmer received a grant of 51,280 stock options with an exercise price of $12.92, vesting in equal thirds over three years, indicating company confidence in future performance and aligning insider interests with shareholders.
The option grant was dated 04/24/2026 with a 10-year expiration (04/24/2036), representing standard equity compensation practices for board members with meaningful potential value at higher stock prices.
This is a routine equity grant with no indication of insider selling or portfolio rebalancing, which is neutral to slightly positive as it demonstrates retained confidence in the company by a board member.

Current Report Filed: 2026-04-27

Dr. Daniel Gilmer, age 39, has been appointed to the Board of Directors effective April 24, 2026, indicating the company is refreshing its board composition with presumably new expertise or perspectives.
Dr. Gilmer will receive a standard non-management director package including a $40,000 annual cash retainer and an option award for 51,280 shares vesting over three years, representing a modest equity stake aligned with typical director compensation.
No material conflicts of interest exist with Dr. Gilmer's appointment—the filing confirms no family relationships with existing officers, no undisclosed arrangements, and no material financial interests requiring disclosure.
The appointment shows no indication of unusual circumstances or related party transactions, suggesting a routine board expansion rather than a response to governance or leadership crises.

Current Report Filed: 2026-03-25

Armata Pharmaceuticals announced its financial results for Q4 2025 and the full fiscal year 2025, indicating the company's operational and financial performance for the period.
The filing does not mention any material agreements, leadership changes, or other significant events, suggesting a relatively routine quarterly earnings report.
Without additional details on the company's financial performance, revenue trends, guidance, or other key metrics, it is difficult to assess the overall significance of this filing for investors.

Annual Report Filed: 2026-03-25

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of phage therapy products to treat bacterial infections. The company's 10-K filing indicates that it has made progress in its research and development efforts, including advancing its lead product candidate into clinical trials.
The filing also highlights Armata's financial position, with the company reporting an increase in cash and cash equivalents compared to the prior year. However, the company continues to incur significant research and development expenses, which may impact its profitability in the near term.
Armata has entered into several strategic partnerships and collaborations, including with the Medical Technology Enterprise Consortium and the Cystic Fibrosis Foundation. These partnerships may provide additional funding and support for the company's ongoing research and development activities.

Current Report Filed: 2026-03-19

Armata Pharmaceuticals, Inc. has delayed the announcement of its Q4 and full-year 2025 financial results, indicating potential issues that could impact the company's financial performance.
The company provided a corporate update, which may contain important information about its operations, pipeline, or strategic direction that could affect investor sentiment.
Investors should closely monitor any further developments or announcements from Armata Pharmaceuticals, as the delay in financial reporting could signal more significant events or changes within the company.

Current Report Filed: 2026-01-26

Armata Pharmaceuticals has extended the maturity dates of its existing credit agreements with Innoviva Strategic Opportunities LLC to June 1, 2027, providing the company with continued access to financing.
The company has also extended the expiration dates of four outstanding warrant certificates held by Innoviva Sub to January 26, 2031, potentially increasing Innoviva's ownership stake in the future.
The amendments to the credit agreements and warrant certificates were made in conjunction with an amendment to the existing Voting Agreement between Armata, Innoviva, and Innoviva Sub, aligning the parties' interests.

Current Report Filed: 2026-01-13

Armata Pharmaceuticals announced the conclusion of an End-of-Phase 2 written response from the FDA and plans to advance its Staphylococcus aureus bacteriophage product candidate, AP-SA02, into a Phase 3 clinical study for complicated S. aureus bacteremia.
The company is progressing its lead product candidate, AP-SA02, through the clinical development pipeline, which could potentially lead to a future regulatory submission and approval for the treatment of complicated S. aureus bacteremia.
This announcement represents an important milestone for Armata as it moves closer to potentially bringing a new therapy option to patients suffering from this serious bacterial infection.

Important Information